Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Instem Plc LSE:INS London Ordinary Share GB00B3TQCK30 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 680.00 670.00 690.00 680.00 680.00 680.00 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 25.7 -0.9 -5.7 - 142

Instem Share Discussion Threads

Showing 851 to 872 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
21/11/2016
07:42
Looking at the price graph above who said info doesn't leak if that price move is from last Friday (I didn't check)? Hold - these are delays and the foundations are still sound and the 2017 looking to have not been harmed.
p1nkfish
29/10/2016
02:06
Sbs went private. Crx likely to be acquired. Who next?
p1nkfish
06/9/2016
17:19
Pleasing to see this rise. Not many of us here so all the best whoever is on the same raft.I hold crx, held sbs, hold odx. A useful UK biotechnology grouping with ins.
p1nkfish
25/8/2016
11:56
Video interview with Phil Reason https://www.youtube.com/watch?v=Cbdhe_Yx6CY Instem PLC (LON:INS) chief executive Phil Reason tells Proactive Investors that the company wants to “dominate” niche markets after it announced a solid first six months of trading in 2016. “We think we can do as we do in many other areas of our business and be a market leader in a particular niche,” Reason says. “We have some particular areas where we think we can dominate some of those niches.” Reason adds that the biotech industry, the company’s main market, has been “buoyant” for the last couple of years and he expects it to remain that way for the foreseeable future. “The contact research organisations that make up a lot of our client base today, their facilities are generally full as they conduct probably the largest numbers of studies they’ve ever enjoyed.”
proactivest
16/8/2016
11:55
Yup. One of my larger holdings.
wjccghcc
16/8/2016
11:50
Anyone else here. As bio turns round I expect this to move up a gear. Steady as she goes in the meantime.
p1nkfish
31/5/2016
23:02
Sensible looking acquisition.
p1nkfish
05/4/2016
15:40
Video interview with Nigel Goldsmith http://tinyurl.com/zgkchvb Nigel Goldsmith, chief financial officer of Instem PLC (LON:INS) tells Proactive the firm had an “exceptionally good year in 2015”, which has given it a “very strong platform” for this year. The company, which develops software used in clinical trials, recorded significant year-on-year growth in 2015 as its main markets continue to expand. Revenues increased by 22% in the 12 months to December 31 to £16.3mln, £10mln of which were recurring. Instem also increased its cash reserves, and Goldsmith says this, combined with a £5mln fundraise, will allow the company to look at “new acquisitions” in a “fragmented sector” with “lots of opportunities”.
proactivest
15/1/2016
11:49
p1nkfish - is there any link to Instem wrt your posted Telegraph article?
brummy_git
15/1/2016
11:48
And this has what to do with Instem? They provide software for managing data for preclinical and early stage clinical drugs. Nothing to do with the drugs themselves.
wjccghcc
15/1/2016
11:37
HTtp://www.telegraph.co.uk/news/12101445/Botched-clinical-trial-in-France-leaves-one-brain-dead-and-five-hospitalised.html
p1nkfish
11/1/2016
22:22
Trading statement due any day? Past few years has been around now.
timtom2
18/12/2015
16:53
Lovely move today.
timtom2
15/5/2015
12:33
I bought quite a few in the 130-140p area. They're market leaders in their niche but are subject to pharma R&D cutbacks every so often so have the odd setback. Usually a good opportunity to buy.
wjccghcc
15/5/2015
10:04
Rise in short time from 135p to well over 200p and no postings. A huge contract win. Very strange BB. Just bought in, a small purchase, after over a year watching this one.
greek islander
27/2/2015
12:02
Video interview with CEO Phil Reason http://tinyurl.com/ob3bujk Phil Reason, the chief executive of Instem (LON:INS), says he is very excited by the opportunity offered by Centrus-submit solution, which enables non-clinical data to be sent to the FDA by electronically rather than on paper. ‘That’s got a huge potential to reduce the amount of time it takes a regulatory reviewer to complete their review of a regulatory submission and accelerate the pace at which a new drug can come to market,’ Reason explains. Instem’s CEO also discusses the newsflow that he hopes will drive the share price higher.
proactivest
20/9/2013
09:19
Results due Wednesday.
m.t.glass
12/7/2013
15:18
Just sold my lot as I think over extended in the short term however will look to go back in at some point
parvez
11/7/2013
15:45
Looking good, difficult to buy any quantity
tech
03/7/2013
07:32
I did pick these up again and believe that these are set to take off with more positive news
parvez
02/7/2013
18:01
Nice deal guys, look forward to more of these and I'll top up my holding
fastbuck
13/5/2013
22:59
I believe this company is now back on a growth path following positive contract comments made in March, the US Govt deal in February and the Chinese deal in April. Add in the add-on acquisition expanding the product offering and expanding the customer base for cross selling opportunities.On a historic PE of circ 12 I picked up shares today, the first deal of many if the company delivers at interims!!
fastbuck
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
ADVFN Advertorial
Your Recent History
LSE
INS
Instem
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210517 12:12:37